Ellen Sigal
Showing 1–3 of 3 transcripts.
- Milken Institute1h 3m
In Service of a Healthier Tomorrow | Global Conference 2025
Esther Krofah, Gregory Case, Judy Faulkner, Robert Ford, Pablo Legorreta, Ellen Sigal, Greg Case
Leading industry figures including Epic's Judy Faulkner and Aon's Greg Case outline a strategic roadmap for the US healthcare ecosystem to reach 2035, aiming to resolve systemic tensions between biomedical innovation and workforce deficits through widespread AI automation and GLP-1 cost management. The panel identifies critical risks such as proposed 40% cuts to NIH funding, FDA staffing reductions, and regulatory bottlenecks that threaten to undermine US leadership in global life sciences despite breakthroughs like xenotransplantation. Concluding that hope is not a strategy, the consensus calls for immediate cross-sector collaboration to align incentives, secure foundational research funding, and modernize infrastructure to prevent China from seizing global health dominance.
- Milken Institute1h 2m
Lessons Learned from COVID-19: Are There Silver Linings for Biomedical Innovation?
Esther Krofah, Francis Collins, Richard Moscicki, Ellen Sigal, Janet Woodcock
Hosted by Faster Cures, a webinar convened NIH officials and industry leaders to analyze the COVID-19 pandemic's acceleration of biomedical innovation, highlighting achievements such as the ACTIV partnership's master protocols and the RADx initiative's diagnostic scaling. The discussion detailed how the crisis forced a shift toward competitive collaboration, decentralized trials, and the successful achievement of diverse vaccine trial enrollment, while simultaneously exposing critical infrastructure gaps in clinical trial execution and real-world data integration. Panelists concluded with a consensus that emergency-driven reforms must be institutionalized through permanent policy changes and public-private partnerships to sustain preparedness for future health threats.
- Milken Institute1h 1m
A Journey to the Cutting Edge of Bioscience: Cancer as a Case Study
Margaret Anderson, Greg Friberg, Douglas Lowy, Fouad Namouni, Ellen Sigal, Nikhil Wagle, Angie Wilson, Sebastian Hermelin
Advancing from a generalized approach to highly personalized medicine, oncology has achieved unprecedented five-year survival rates for metastatic melanoma and long-term remission in lung cancer through immunotherapy and combination strategies. Despite these clinical successes, the sector faces significant hurdles including low clinical trial enrollment in community settings, fragmented electronic health record data, and ethical barriers to information sharing. To overcome these obstacles, stakeholders are leveraging artificial intelligence, patient-centered initiatives like "Count Me In," and predictive modeling to integrate community biospecimens and accelerate the development of functional cures.